Amgen’s Denosumab Gets Priority Review

Published July 20, 2010

Amgen’s Denosumab Gets Priority Review
The U.S. Food and Drug Administration granted priority review designation to Amgen’s new drug denosumab for the treatment of bone problems in cancer patients.
Read more on San Fernando Valley Business Journal